HCA
INSY

Harbour Capital Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Harbour Capital Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-600
Closed -$6.31K – 642
2017
Q1 		$6.31K Buy
+600
New +$6.39K ﹤0.01% 584
2015
Q1 		– Sell
-13,450
Closed -$284K – 218
2014
Q4 		$284K Buy
+13,450
New +$266K 0.2% 151

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harbour Capital Advisors's INSY Position: Q2 2017 in Review

Harbour Capital Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 600 shares — an estimated $6.31K sold.

Harbour Capital Advisors first reported a position in INSY in Q4 2014 and held it in 2 quarters. The position peaked at $284K in Q4 2014. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • Harbour Capital Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Harbour Capital Advisors sold 600 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $6.31K.
  • Harbour Capital Advisors first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Harbour Capital Advisors's Insys Therapeutics, Inc. position peaked at $284K in Q4 2014.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Harbour Capital Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.